COMPLETED trials
Read more about the completed trials that MedVadis Research is involved with. Contact us anytime if you would like to volunteer or have any questions.
Adult Migraine
Study ID 235
A Phase 2/3 Open-label, Long-Term, Safety Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine
Medical Conditions:
Related Conditions:
Sex/Gender:
Age:
Study Completed!
Study ID 240
Phase 3: Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV- 3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine
Medical Conditions:
Adult Migraine
Related Conditions: Adult Migraine
Sex/Gender:
Age:
Study Completed!
Study ID 245
An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Medical Conditions:
Migraine
Related Conditions: Migraine
Sex/Gender:
Age:
Study Completed!
Study ID 250
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2 Study of ABP-450 (prabotulinumtoxinA) Purified Neurotoxin Complex for the Prevention of Migraine Headache
Medical Conditions:
Adult Migraine
Related Conditions: Adult Migraine
Sex/Gender:
Age:
Study Completed!
Study ID 251
A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention
Medical Conditions:
Adult Migraine
Related Conditions: Adult Migraine
Sex/Gender:
Age:
Study Completed!
Study ID 261
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Medical Conditions:
Adult Migraine
Related Conditions: Adult Migraine
Sex/Gender:
Age:
Study Completed!
Study ID 285
A Randomized, Multicenter, Dose-Blinded, Phase 2 Extension Study of ABP-450 (prabotulinumtoxinA) Purified Neurotoxin Complex for the Prevention of Migraine Headache
Medical Conditions:
Related Conditions:
Sex/Gender:
Age:
Study Completed!
Study ID 297
Phase 2 Double-Blind, Randomized, Placebo Controlled, Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine
https://medvadis.com/clinical-trials/adult-migraine/nct06603623/
Medical Conditions:
Adult Migraine
Related Conditions: Adult Migraine
Sex/Gender:
Age:
Study Completed!
Alzheimer's Disease
Study ID 258
A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease
Medical Conditions:
Alzheimer's Disease
Related Conditions: Alzheimer's Disease
Sex/Gender:
Age:
Study Completed!
Study ID 263
A Phase 3, Randomized, Double-Blind Placebo-Controlled Parallel-Group 76-Week Study Evaluating The Safety And Efficacy Of Two Doses Of Simufilam In Subjects With Mild-To-Moderate Alzheimer's Disease
Medical Conditions:
Alzheimer's Disease
Related Conditions: Alzheimer's Disease
Sex/Gender:
Age:
Study Completed!
Study ID 277
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study of Buntanetap in Participants with Mild to Moderate Alzheimer’s Disease
Medical Conditions:
Alzheimer's Disease
Related Conditions: Alzheimer's Disease
Sex/Gender:
Age:
Study Completed!
Chronic Knee Pain
Study ID 237
Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Osteoarthritis
Medical Conditions:
Chronic Knee Pain
Related Conditions: Chronic Knee Pain
Sex/Gender:
Age:
Enrollment Complete.
Study ID 246
Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Osteoarthritis
Medical Conditions:
Chronic Knee Pain
Related Conditions: Chronic Knee Pain
Sex/Gender:
Age:
Enrollment Complete.
Study ID 254
Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Osteoarthritis
Medical Conditions:
Chronic Knee Pain
Related Conditions: Chronic Knee Pain
Sex/Gender:
Age:
Enrollment Complete.
Chronic Low Back Pain
Study ID 299
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Who Have Obesity or Overweight and Chronic Low Back Pain (TRIUMPH-7)
The main purpose of this study is to evaluate the efficacy and safety of retatrutide in relieving chronic low back pain in participants who have obesity or overweight. Participation in the study will last about 80 weeks.
Medical Conditions:
Chronic Back Pain
Related Conditions: Chronic Back Pain
Sex/Gender: Male & Female
Age: 18 Years and Older
Study Completed!
Study ID 238
Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Chronic Low Back Pain
Medical Conditions:
Chronic Back Pain
Related Conditions: Chronic Back Pain
Sex/Gender:
Age:
Study Completed!
Study ID 247
Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Chronic Low Back Pain
Medical Conditions:
Chronic Back Pain
Related Conditions: Chronic Back Pain
Sex/Gender:
Age:
Study Completed!
Study ID 255
Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Chronic Low Back Pain
Medical Conditions:
Chronic Back Pain
Related Conditions: Chronic Back Pain
Sex/Gender:
Age:
Study Completed!
Study ID 271
A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Chronic Low Back Pain
Medical Conditions:
Chronic Back Pain
Related Conditions: Chronic Back Pain
Sex/Gender:
Age:
Study Completed!
Diabetic Neuropathy
Study ID 239
Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Diabetic Peripheral Neuropathic Pain
Medical Conditions:
Diabetic Neuropathy
Related Conditions: Diabetic Neuropathy
Sex/Gender:
Age:
Study Completed!
Study ID 248
Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Diabetic Peripheral Neuropathic Pain
Medical Conditions:
Diabetic Neuropathy
Related Conditions: Diabetic Neuropathy
Sex/Gender:
Age:
Study Completed!
Study ID 256
Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Diabetic Peripheral Neuropathic Pain
Medical Conditions:
Diabetic Neuropathy
Related Conditions: Diabetic Neuropathy
Sex/Gender:
Age:
Study Completed!
Study ID 260
A Phase 2, Randomized, Double-blind, Active-controlled, Dose-ranging, Parallel-design Study of the Efficacy and Safety of VX-548 in Subjects With Painful Diabetic Peripheral Neuropathy
Medical Conditions:
Diabetic Neuropathy
Related Conditions: Diabetic Neuropathy
Sex/Gender:
Age:
Study Completed!
Study ID 268
A Study to Evaluate Efficacy and Safety of GSK3858279 in Diabetic Peripheral Neuropathic Pain (NEPTUNE-17)
Medical Conditions:
Diabetic Neuropathy
Related Conditions: Diabetic Neuropathy
Sex/Gender:
Age:
Study Completed!
Study ID 272
A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain
Medical Conditions:
Diabetic Neuropathy
Related Conditions: Diabetic Neuropathy
Sex/Gender:
Age:
Study Completed!
Study ID 286
A Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Ranging Study to Evaluate LY3556050 in Adult Participants with Diabetic Peripheral Neuropathic Pain
Medical Conditions:
Diabetic Neuropathy
Related Conditions: Diabetic Neuropathy
Sex/Gender:
Age:
Study Completed!
Obesity
Study ID 299
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Who Have Obesity or Overweight and Chronic Low Back Pain (TRIUMPH-7)
The main purpose of this study is to evaluate the efficacy and safety of retatrutide in relieving chronic low back pain in participants who have obesity or overweight. Participation in the study will last about 80 weeks.
Medical Conditions:
Obesity
Related Conditions: Obesity
Sex/Gender: Male & Female
Age: 18 Years and Older
Enrollment Complete!
Study ID 279
A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants with Type 2 Diabetes Mellitus who have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-2)
The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have obesity or overweight (J1I-MC-GZBK master protocol) including a subset of participants who have obstructive sleep apnea (OSA) (J1I-MC-GSA2). The study will last about 89 weeks and will include up to 24 visits.
Medical Conditions:
Obesity
Related Conditions: Obesity
Sex/Gender: Male & Female
Age: 18 Years and Older
Enrollment Complete!
Study ID 280
A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants with Severe Obesity and Established Cardiovascular Disease (TRIUMPH-3)
The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks.
Medical Conditions:
Obesity
Related Conditions: Obesity
Sex/Gender: Male & Female
Age: 18 Years and Older
Enrollment Complete!
Study ID 281
A Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants who have Obesity or Overweight and Osteoarthritis of the Knee: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-4)
The main purpose of this study is to evaluate the safety and efficacy of retatrutide once-weekly in participants who have obesity or are overweight and have osteoarthritis (OA) of the knee. The study will lasts about 77 weeks.
Medical Conditions:
Obesity
Related Conditions: Obesity
Sex/Gender: Male & Female
Age: 18 Years and Older
Enrollment Complete!
Study ID 278
A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants without Type 2 Diabetes who have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1)
The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA) (J1I-MC-GOA1) or who have obstructive sleep apnea (OSA) (J1I-MC-GSA1). This study will last about 89 weeks and will include up to 24 visits. Addendum (2) is optional and available to approximately 500 participants to continue treatment with retatrutide for up to an additional 24 weeks.
Medical Conditions:
Obesity
Related Conditions: Obesity
Sex/Gender: Male & Female
Age: 18 Years and Older
Enrollment Complete!
Pediatric Migraine
No Results Found.
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.